Redwood City, California-based Armo BioSciences Inc, a late-stage immuno-oncology company has raised about $128 million for its IPO after pricing its over 7.5 million shares at $17 per share. The stock began trading January 26, 2018 on the NASDAQ under the ticker symbol “ARMO.” Jefferies LLC, Leerink Partners LLC and BMO Capital Markets Corp are the lead underwriters. Armo’s pre-IPO backers were Qiming Venture Partners, Decheng Capital, Sequoia Capital, Quan Capital, RTW Investments, Kleiner Perkins Caufield and Byers, OrbiMed, DAG Ventures, NanoDimension, HBM Healthcare Investments and GV.
REDWOOD CITY, Calif., Jan. 25, 2018 /PRNewswire/ — ARMO BioSciences, Inc. (“ARMO”), a late-stage immuno-oncology company, today announced the pricing of its initial public offering of 7,529,412 shares of its common stock at a price to the public of $17.00 per share for total gross proceeds of approximately $128.0 million. The shares are expected to begin trading on The Nasdaq Global Select Market on January 26, 2018 under the ticker symbol “ARMO.” The offering is expected to close on January 30, 2018, subject to customary closing conditions.
In addition, ARMO has granted the underwriters a 30-day option to purchase up to an additional 1,129,411 shares of common stock at the public offering price, less underwriting discounts and commissions.
Jefferies LLC, Leerink Partners LLC and BMO Capital Markets Corp. are acting as joint book-running managers for the proposed offering. Baird is acting as co-manager.
The offering will be made only by means of a prospectus. When available, copies of the final prospectus related to the offering may be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at 877-547-6340 or by email at Prospectus_Department@Jefferies.com; from Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at 800-808-7525 ext. 6132 or by email at Syndicate@Leerink.com; or from BMO Capital Markets Corp., Attention: Equity Syndicate Department, 3 Times Square, 25th Floor, New York, NY 10036, by telephone at 800-414-3627 or by email at email@example.com.
A registration statement relating to these securities was filed with, and declared effective by, the U.S. Securities and Exchange Commission on January 25, 2018. Copies of the registration statement can be accessed through the SEC’s website at www.sec.gov. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About ARMO BioSciences
ARMO BioSciences is a late-stage immuno-oncology company that is developing a pipeline of novel, proprietary product candidates that activate the immune system of cancer patients to recognize and eradicate tumors. The Company’s lead product candidate, AM0010 (pegilodecakin), is being evaluated in an ongoing Phase 1/1b clinical trial as a therapy for pancreatic cancer, non-small cell lung cancer, renal cell carcinoma, colorectal carcinoma and melanoma. In addition, AM0010 is being evaluated in a Phase 3 randomized pivotal clinical trial in pancreatic cancer patients, which compares a combination of AM0010 and FOLFOX to FOLFOX alone, as a second-line therapy after tumor progression during or following a gemcitabine-containing regimen. The Company also has a number of other immuno-oncology product candidates aimed at treating a variety of cancers in combination with standard of care treatments and emerging immunotherapies. These candidates are in various stages of pre-clinical development, and include: AM0001, an anti-PD-1 checkpoint inhibitor; AM0003, an anti-LAG-3 checkpoint inhibitor; AM0015, a form of recombinant human Interleukin-15 (IL-15) cytokine; and AM0012, a form of recombinant human Interleukin-12 (IL-12) cytokine.